Shots:

• Intima gets an non-exclusive clinical & commercial rights to use MaxCyte’s Flow Electroporation technology & ExPERT platform that helps to accelerate the development of solid tumor cell-therapy products. In exchange, MaxCyte is eligible to receive platform licensing fees & program-related milestones
• The company is currently advancing the genetically eTIL programs in a P-I/II clinical study that targets the immune checkpoint CISH in patients with gastrointestinal and colon cancers
• ExPERT platform delivers the high-end performance for biological and cellular therapeutics through high transfection efficiency, seamless scalability and enhanced functionality

Ref: Globe Newswire | Image: Globe Newswire